Fate Therapeutics

Allogeneic CAR-T biotechs fight to escape 'nuclear winter'

As autologous CAR-T continues to improve and Big Pharma pumps big cash into next-gen approaches, is there room left at the table for allogeneic CAR-T?

Darren Incorvaia Feb 11, 2026 11:00am

J&J, Bayer, Santa Ana, Regenxbio and more—Chutes & Ladders

Jun 14, 2024 8:30am

Fate resets as J&J deal ends, cutting pipeline and head count

Jan 6, 2023 6:50am

Former AbbVie R&D chief tapped to run Tessera—Chutes & Ladders

Jun 3, 2022 9:30am

cancer cell surrounded by killer T cells

Bristol Myers Squibb-backed Clade nabs a meaty $87M series A

Nov 3, 2021 7:00am

Fate Therapeutics' stock drops on blood cancer readout

Aug 20, 2021 8:20am